Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer [0.03%]
液体活检在晚期非小细胞肺癌临床管理中的验证研究：血浆游离DNA检测
Vidya H Veldore,Anuradha Choughule,Tejaswi Routhu et al.
Vidya H Veldore et al.
Plasma cell-free tumor DNA, or circulating tumor DNA (ctDNA), from liquid biopsy is a potential source of tumor genetic material, in the absence of tissue biopsy, for EGFR testing. Our validation study reiterates the clinical utility of ctD...
Bevacizumab in the treatment of NSCLC: patient selection and perspectives [0.03%]
贝伐单抗在非小细胞肺癌治疗中的患者选择及展望
Alessia E Russo,Domenico Priolo,Giovanna Antonelli et al.
Alessia E Russo et al.
Non-small-cell lung cancer (NSCLC) represents about 85% of all lung cancers, and more than half of NSCLCs are diagnosed at an advanced stage. Chemotherapy has reached a plateau in the overall survival curve of about 10 months. Therefore, in...
Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer [0.03%]
前期格拉斯哥预后评分和营养指数可预测小细胞肺癌患者的总生存期
Seigo Minami,Yoshitaka Ogata,Shouichi Ihara et al.
Seigo Minami et al.
Background: Various biomarkers have been shown to predict prognosis in various types of cancers. However, these biomarkers have not been studied in advanced small cell lung cancer (SCLC). The modified Glasgow prognostic s...
Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature [0.03%]
奥希替尼耐药后组织和血浆ctDNA中EGFR G796S突变的病例报道及文献复习
Samuel J Klempner,Pareen Mehta,Alexa B Schrock et al.
Samuel J Klempner et al.
Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) is a universal event and limits clinical efficacy. The third-generation EGFR inhibitor osimertinib is active in EGFR-mutant/T790M positive non-s...
Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response [0.03%]
胃泌素释放肽（ProGRP）作为小细胞肺癌诊断、监测及评估治疗反应的生物标志物
Ewa Wojcik,Jan Kanty Kulpa
Ewa Wojcik
Lung cancer belongs to malignant tumors that possess the highest rates of morbidity and mortality in the world. A number of morphological, biological and clinical features justify the distinction of small-cell carcinoma with respect to the ...
65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer [0.03%]
65 Plus：贝伐单抗联合培美曲塞或卡铂治疗晚期非鳞状细胞非小细胞肺癌患者的开放标签研究
Wolfgang Schuette,Claus-Peter Schneider,Walburga Engel-Riedel et al.
Wolfgang Schuette et al.
Background: The aim of the study was to investigate in terms of noninferiority the efficacy and safety of a monochemotherapy regimen of pemetrexed plus bevacizumab (BevPem) versus carboplatin/pemetrexed plus bevacizumab (...
nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy [0.03%]
纳妥铂紫杉醇/卡铂诱导治疗鳞状非小细胞肺癌：化疗期间纵向生活质量分析
Michael Thomas,David R Spigel,Robert M Jotte et al.
Michael Thomas et al.
Background: Longitudinal data on the impact of treatment on quality of life (QoL) in advanced non-small cell lung cancer (NSCLC) are limited. In this palliative setting, treatment that does not deteriorate QoL is key. Her...
Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan [0.03%]
晚期非小细胞肺癌患者的实际治疗模式在日本多中心回顾性队列研究中的分析
Hiroshi Isobe,Kiyoshi Mori,Koichi Minato et al.
Hiroshi Isobe et al.
Background: Recommended therapies for advanced/metastatic non-small cell lung cancer (NSCLC) have changed with the advent of targeted therapies. The objectives of this retrospective chart review study were to describe tre...
Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting [0.03%]
纳武利尤单抗联合化疗对比吉西他滨联合化疗用于晚期肺鳞癌一线治疗的有效性和安全性：美国社区肿瘤机构的资料分析
Raja Mudad,Manish B Patel,Sandra Margunato-Debay et al.
Raja Mudad et al.
Introduction: Real-world comparative effectiveness, safety, and supportive care use of nab-paclitaxel plus carboplatin vs gemcitabine plus platinum were analyzed in patients with advanced or metastatic squamous cell non-s...
Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib [0.03%]
brigatinib在克唑替尼耐药或不耐受的转移性ALK阳性非小细胞肺癌患者中的潜力
Rohit K Jain,Hongbin Chen
Rohit K Jain
In the last decade, there have been major therapeutic advances in the management of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. Crizotinib was the first approved ALK inhibitor with significant benefit...